Girentuximab I-124

DB15025Investigational

Girentuximab I-124 is under investigation in clinical trial NCT01762592 (REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT).

Mechanism: Pharmacologically active on Carbonic anhydrase 9
Curator reviewed
Also known as: IODINE (124I) GIRENTUXIMAB · Iodine i 124 girentuximab

Resolves to

Compound

UNIIP0I0FT82VKCAS1011710-99-8

Targets

Q16790CA9

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Girentuximab I-124, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account